Indivior PLC (INDV) - What Are Analysts Thinking About This Stock?

Key Points

• Analyst sentiment is broadly positive: Six analysts give Indivior a consensus “Buy” rating, with an average 12-month price target of $46.40.
• Quarterly results beat expectations: Indivior reported EPS of $1.32 versus estimates of $1.06 and revenue of $356 million versus expectations of $329.35 million.
• The company paid a special dividend of $8.13 per share on November 6 to shareholders of record as of October 30.

Indivior PLC (NASDAQ:INDV - Get Free Report) has been assigned a consensus rating of "Buy" from the six analysts that are currently covering the stock, Marketbeat reports. One analyst has rated the stock with a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the company. The average twelve-month price target among analysts that have updated their coverage on the stock in the last year is $46.40.

Several brokerages have recently weighed in on INDV. Wall Street Zen downgraded shares of Indivior from a "strong-buy" rating to a "buy" rating in a research note on Saturday, October 31st. Craig Hallum reaffirmed a "buy" rating and set a $53.00 price target on shares of Indivior in a research note on Tuesday, August 4th. Zacks Research upgraded shares of Indivior from a "hold" rating to a "strong-buy" rating in a report on Friday, October 2nd. Barclays boosted their target price on Indivior from $43.00 to $45.00 and gave the company an "overweight" rating in a research report on Wednesday, October 28th. Finally, Weiss Ratings cut Indivior from a "buy (b-)" rating to a "hold (c+)" rating in a research note on Thursday, September 24th.

Indivior Price Performance

Shares of INDV stock opened at $28.21 on Monday. Indivior has a 1 year low of $27.68 and a 1 year high of $42.81. The stock's 50 day simple moving average is $34.90 and its two-hundred day simple moving average is $35.62. The company has a market cap of $3.33 billion, a PE ratio of 7.88 and a beta of 0.84.

Indivior (NASDAQ:INDV - Get Free Report) last announced its earnings results on Thursday, October 29th. The company reported $1.32 EPS for the quarter, topping analysts' consensus estimates of $1.06 by $0.26. The firm had revenue of $356.00 million during the quarter, compared to analysts' expectations of $329.35 million. Indivior had a negative return on equity of 418.04% and a net margin of 32.75%. Equities research analysts expect that Indivior will post 3.66 EPS for the current year.

Indivior Announces Dividend

The firm also recently announced a special dividend, which was paid on Friday, November 6th. Stockholders of record on Friday, October 30th were given a dividend of $8.13 per share. The ex-dividend date was Tuesday, November 3rd.

Insider Buying and Selling at Indivior

In related news, CAO Woodrow D. Anderson bought 1,500 shares of the stock in a transaction dated Thursday, August 27th. The stock was purchased at an average cost of $35.69 per share, with a total value of $53,535.00. Following the completion of the purchase, the chief accounting officer owned 27,638 shares of the company's stock, valued at $986,400.22. This trade represents a 5.74% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Company insiders own 0.74% of the company's stock.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the stock. Illinois Municipal Retirement Fund raised its stake in Indivior by 1.0% in the third quarter. Illinois Municipal Retirement Fund now owns 62,933 shares of the company's stock worth $2,256,000 after buying an additional 611 shares in the last quarter. Rockefeller Capital Management L.P. lifted its holdings in Indivior by 512.4% during the fourth quarter. Rockefeller Capital Management L.P. now owns 1,286 shares of the company's stock worth $46,000 after buying an additional 1,076 shares during the period. TD Waterhouse Canada Inc. bought a new stake in Indivior during the 2nd quarter valued at $63,000. GAMMA Investing LLC purchased a new position in shares of Indivior in the 2nd quarter valued at $66,000. Finally, China Universal Asset Management Co. Ltd. raised its position in shares of Indivior by 11.0% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 21,533 shares of the company's stock worth $788,000 after acquiring an additional 2,129 shares in the last quarter. Hedge funds and other institutional investors own 60.33% of the company's stock.

About Indivior

Indivior is a specialty pharmaceutical company focused on developing and providing treatments for substance use disorders and serious mental illness. Its products include medicines for opioid use disorder, such as Sublocade, a long-acting injectable form of buprenorphine, and Suboxone, a buprenorphine-and-naloxone treatment.

The company also markets Opvee, a nasal spray used to reverse opioid overdose, and Perseris, a long-acting injectable treatment for schizophrenia. Indivior develops additional therapies through its research and development programs.

Indivior was formed in 2014 when Reckitt Benckiser separated its pharmaceutical business.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.